Show Summary Details
Page of

Growth factors and cytokines in renal bone disease 

Growth factors and cytokines in renal bone disease
Growth factors and cytokines in renal bone disease

Esther A. González

and Kevin J. Martin

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 10 August 2020

In summary, in addition to the effects of the well known calciotropic hormones, normal bone remodeling appears to depend on the integrated effects of a variety of growth factors and cytokine systems. There are many abnormalities in the setting of chronic kidney disease, not only in circulating hormones, but also in terms of systemic inflammatory responses associated with abnormalities in a variety of cytokines. Since these cytokines appear to impact upon the bone remodeling cycle, they are likely to modify the active cellular processes of bone, and thus alter the manifestations of renal osteodystrophy. Further work is required to specifically delineate their actions on bone, especially in the setting of renal bone disease and to investigate the potential of modifying these cytokine and growth factor pathways with specific therapeutic agents to improve not only the abnormalities of the skeleton, but which might also have the potential to influence calcifications at extraskeletal sites.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.